Klaus Bæk Simonsen

Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ.

The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California.

EntomoPharm ApS is a holding company that develops insect based absorption, distribution, metabolism, or excretion (ADME) models for early drug discovery. It is a contract research organization that offers validated ex vivo blood brain barrier screening model providing customized study design. Its insect assays can be used to screen small-molecule compounds to identify properties of drug leads in both central nervous system drug development and in safety risk identification for peripherally acting drugs. The firm provides models based on the locust migratory to determine the permeability; the in vivo and the ex vivo model. The company was founded by Peter Aadal Nielsen and Gunnar Andersson in 2009 and is headquartered in Hillerod, Denmark.